Ro and Novo Collaborate on Pioneering Research for Wegovy® Pill's Real-World Effectiveness

Introduction

In a significant move within the healthcare sector, Ro, a leading direct-to-patient healthcare company, has joined forces with Novo to embark on a groundbreaking research collaboration. This partnership aims to generate unique real-world evidence surrounding the Wegovy® pill, a medication that has generated considerable interest for its potential in obesity treatment. On September 30, 2026, the preliminary findings from this research were presented at the esteemed EASD Annual Meeting held in Milan, Italy.

Background on Ro and Wegovy® Pill

Ro has emerged as a pivotal player in the healthcare industry, particularly in the realm of GLP-1-related treatments. Since its inception in 2017, Ro has been committed to providing patients across the United States access to essential healthcare services, including telehealth, labs, and pharmacy solutions, all under one integrated platform.
The Wegovy® pill, developed by Novo, represents a major advancement in the treatment of obesity. Designed as a convenient alternative to injectable formulations, this oral medication has been welcomed by both patients and healthcare providers for its ease of use and effectiveness.

The Collaboration

This collaboration builds upon an existing relationship between Ro and Novo, which has been significantly beneficial in expanding patient access to GLP-1 treatments. By launching the Wegovy® pill on its platform on the first day of its market availability and offering long-term savings options, Ro has demonstrated its commitment to improving patient care. The research initiative aims to capture real-world data focusing on patients who transitioned from injectable GLP-1 medications to the Wegovy® pill while utilizing Ro's platform.

Zach Reitano, Co-founder and CEO of Ro, emphasized the importance of this collaborative effort, stating, "Working with Novo, we've made it seamless for patients nationwide to access Wegovy® through Ro's direct-to-patient platform at the best available cash prices." This research initiative looks to delve deeper into patient experiences, aspirations, and treatment trajectories, utilizing the findings to enhance the quality of care through innovative, AI-driven tools.

Focus of the Research

The study presented at the EASD 2026 scrutinized the outcomes among patients dealing with overweight or obesity who successfully transitioned to the Wegovy® pill. Specifically, the research targeted individuals who adhered to the pill's treatment regime for a minimum of three months. This inquiry was co-authored by respected clinical advisors from Ro, Dr. Beverly Tchang and Dr. Louis Aronne.
Findings from this study shed light on the effectiveness of the Wegovy® pill in a real-world setting, showcasing the everyday patient experience—a critical aspect often overlooked in clinical trials.

Future Research Directions

Further collaboration by Ro and Novo is poised to continue at ObesityWeek 2026, scheduled for November 14-17, where they will present additional pioneering research insights. This will include demographic analysis of individuals pursuing the Wegovy® pill treatment, as well as outcomes concerning weight loss, food distractions, and overall quality of life improvements.

Dr. Anna Windle, Group Vice President of Clinical Development at Novo, remarked, "The Wegovy® pill represents an important advancement in obesity care. By expanding our collaboration with Ro, we have an opportunity to generate scaled real-world evidence..."
This ongoing research not only underscores the commitment to patient needs but also enhances understanding of the Wegovy® pill's nuances post-launch.

Conclusion

In summary, the collaboration between Ro and Novo signifies a monumental step in bridging the gap between clinical research and real-world application. By harnessing the power of real-world data, this initiative aims to continually improve patient outcomes and broaden access to critical obesity care. With Ro's comprehensive platform and Novo's innovative pharmaceutical contributions, this partnership is set to redefine standards in direct-to-patient healthcare and obesity management.